NovAliX Conference 2013
Biophysics in Drug Discovery

Developing the Synergy between Biophysics and Medicinal Chemistry to Deliver Better Drugs

BφDD 2013

 Strasbourg, France    October 15-18, 2013

Programme


13:00

Registration

14:00

Social Programme

16:45

Welcome Address

Chair

Dr Takaaki MIURA
CHUGAI PHARMACEUTICAL, Kanagawa, Japan

17:00

KN01 - Biophysical Methods and Fragment Based Drug Discovery: Targeting Protein-Protein Interactions in Cell Regulatory Systems

Prof. Sir Tom BLUNDELL
UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom

18:00

Welcome Reception

08:30

Registration

1st Session - Biophysical Characterisation

Chair

Dr Johannes OTTL
NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland

09:00

PL01 - Binding of Drug Substances to Molecular Targets Investigated by Biophysical Methods

Dr Michael HENNIG
F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland

09:40

PL02 - Enabling GPCR Drug Discovery Through Structural and Biophysical Insights

Dr Rob COOKE
HEPTARES, Hertfordshire, United Kingdom

10:20

Coffee Break

10:50

OC01 - Biophysical Investigations of the Synergistic Activities of Antimicrobial Peptides: New Strategies to Fight Multiresistance

Prof. Burkhard BECHINGER
UNIVERSITY OF STRASBOURG, Strasbourg, France

11:15

OC02 - X-Ray Crystallography, Kinetic Target-Guided Synthesis and NMR to Unravel the Mode of Action of Insulin Degrading Enzyme Modulators

Prof. Rebecca DEPREZ-POULAIN
UNIVERSITY OF LILLE, Lille, France

11:40

PL03 - Biophysics to Drive Lead Discovery

Dr Matthias FRECH
MERCK, Darmstadt, Germany

12:20

Lunch and Networking

2nd Session - Mechanistic Analysis

Chair

Prof. Helena DANIELSON
UPPSALA UNIVERSITY, Uppsala, Sweden

14:00

PL04 - Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics: DOT1L and EPZ-5676

Dr Ann BORIACK-SJODIN
EPIZYME, Cambridge, United States

14:40

PL05 - Investing in Knowledge: Combining Biophysical Data in Fragment-Based Drug Discovery

Dr Glyn WILLIAMS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom

15:20

OC03 - Residence and Recognition Time and their Use for Structure Kinetic Relationships and for Judging Efficacy of Lead Series

Dr Markku HÄMÄLÄINEN
GE HEALTHCARE BIO-SCIENCES, Uppsala, Sweden

15:45

OC04 - Pharmacokinetics and the Drug-Target Residence Time Concept

Dr Göran DAHL
ASTRAZENECA, Mölndal, Sweden

16:10

Coffee Break

16:45

OC05 - Bringing Light into Antibody Binding Characteristics in Crude Extracts by Means of FCCS

Dr Frank BECKER
INTANA BIOSCIENCE GMBH, Planegg, Germany

17:10

PL06 - Can we Use Kinetics and Thermodynamics to Guide Drug Discovery?

Dr Geoff HOLDGATE
ASTRAZENECA, Macclesfield, United Kingdom

Chair

Dr Geoff HOLDGATE
ASTRAZENECA, Macclesfield, United Kingdom

17:50

KN02 - Molecular Mechanism of Action (MMOA) in Drug Discovery

Dr David SWINNEY
IRND3, Mountain View, United States

20:00

Entertainment (optional & subject to prior registration)

3rd Session - Emerging Technologies

Chair

Dr Matthias FRECH
MERCK, Darmstadt, Germany

09:00

PL07 - Label-Free, Immobilisation-Free Interaction Studies Using Microscale Thermophoresis

Dr Stefan DUHR
NANOTEMPER, Munich, Germany

09:40

PL08 - Backscattering Interferometry: An Enabling Drug Development Technology

Dr Darryl BORNHOP
VANDERBILT UNIVERSITY, Nashville, United States

10:20

OC06 - Detection and Analysis of Proteins with an Electro-Switchable DNA Chip

Dr Ralf STRASSER
DYNAMIC BIOSENSORS GMBH, Martinsried, Germany

10:45

Coffee Break

11:15

OC07 - Binding Rate Constants Measured on Microliter Volume Using On-Chip Temperature Modulation and Fluorescence Lock-In Detection

Dr Charlie GOSSE
CNRS, Marcoussis, France

11:40

OC08 - CRYO-TEM: The Way to Answer Real Biological Questions through Unraveling the 3D Mechanistics of Protein

Dr Thomas WOHLFARTH
FEI, Eindhoven/Acht, The Netherlands

12:05

PL09 - Towards Personalised Cancer Medicine with New NMR Tools to Probe Small GTPase Proteins

Dr Chris MARSHALL
UNIVERSITY OF TORONTO, Toronto, Canada

12:45

Lunch and Networking

14:25

Poster Session

15:55

Coffee Break

16:25

Round-table discussion on hot topics, emerging trends, and new techniques & approaches; sharing of experience and questions from the audience to a panel of experts

Moderator

Dr Glyn WILLIAMS
ASTEX PHARMACEUTICALS, Cambridge, United Kingdom

17:10

Poster Prizes

Chair

Dr Michael HENNIG
F. HOFFMANN-LA ROCHE LTD., Villigen, Switzerland

17:25

KN03 - Combining X-Ray Crystallography and Single-Molecule Methods to Probe Antibiotic Inhibition of Translation

Prof. Jamie CATE
UNIVERSITY OF CALIFORNIA, Berkeley, United States

20:00

Conference Dinner (optional & subject to prior registration)

4th Session - Biophysical Methods for Identifying Hits and Leads

Chair

Dr Herbert NAR
BOEHRINGER INGELHEIM, Biberach, Germany

09:00

PL10 - Application of SPR Biosensors Throughout the Drug Discovery Process

Prof. Helena DANIELSON
UPPSALA UNIVERSITY, Uppsala, Sweden

09:40

PL11 - Finding Active Ligands to kRAS Using Solution State NMR

Dr Till MAURER
GENENTECH, South San Francisco, United States

10:20

Coffee Break

10:50

OC09 - Identification and Validation of Small Molecule Inhibitors of G Protein Beta 1 Gamma 2

Dr Preeti BAKRANIA
MRC TECHNOLOGY, London, United Kingdom

11:15

OC10 - Fragments at UCB: Implementation of Non-Covalent Mass Spectrometry and 19F NMR as Orthogonal Screening Techniques

Dr Hannah MAPLE
UCB, Slough, United Kingdom

11:40

PL12 - Biophysics in Pharmaceutical Lead Discovery

Dr Johannes OTTL
NOVARTIS INSTITUTE OF BIOMEDICAL RESEARCH, Basel, Switzerland

12:20

Closing Remarks and Departure